RxData

RxData — Curated global market-access event and pricing repository for prescription drugs: HTA publications and appraisals, regulatory decisions, reimbursement/categorisation decisions, and global list prices, normalised into three views (Events, Coverage, Pricing) keyed by drug, indication and manufacturer, with derived net prices produced by disclosed net-price algorithms and pricing forecasts for indications in the top markets (US, Japan, EU5, China, Brazil, Mexico, Canada, Australia). Built by live automated monitoring of 100+ primary sources.. Micro-scale vendor, high-density dataset: 7 …

RxData offers (Alternative, Fundamental, Reference) — Order of 10^6-10^7 normalised rows: every prescription drug x indication x market with one or more regulatory/HTA/reimbursement events plus periodic list and net price observations, ingested continuously from 100+ sources. Coverage claims completeness over prescription drugs ('find results for ANY prescription drug')..

Analogue / comparable-drug benchmarking for launch pricing; value-dossier and HTA evidence construction; indication-level lifetime-value and asset-valuation models (Phase 2/3 transition and in-licence cases are named on the page); pricing-assumption forecasting for top markets; training models that predict reimbursement outcome and net price from drug/indication features; competitive-intensity scoring by indication

The data is with 20 years of history.

Coverage spans US, UK, Europe, Japan, Other; Pharmaceuticals; alternative, fundamental, reference; equities.